LAMP-based electrochemical platform for monitoring HPV genome integration at the mRNA level associated with higher risk of cervical cancer progression.
Nasim Izadi, Johana Strmiskova, Milan Anton...
https://pubmed.ncbi.nlm.nih.gov/39420658/Actively Recruiting
Led by Masaryk Memorial Cancer Institute · Updated on 2026-07-22
35
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to monitor the presence and amount of HPV infection in patients with oropharyngeal carcinoma OPC, a type of head and neck cancer. It focuses on patients undergoing conservative radiation therapy or concurrent chemoradiation therapy. The study evaluates a new electrochemical method for detecting HPV DNA, which has been previously validated for cervical cancer, to better understand HPV viral load dynamics before and during treatment. Participants include patients with HPV-positive OPC and a control group with HPV-negative OPC. The study collects oral swabs, oral cavity washings, and blood samples at set times before treatment, during treatment at week 4, at the end of radiotherapy around week 7, and three months after treatment. This allows comparison of the new detection method to standard quantitative PCR qPCR techniques and helps assess changes in HPV viral load over time. During the study, participants will provide samples at these scheduled points for analysis of viral circulating tumor DNA. Researchers will track the correlation of HPV DNA levels measured by both methods and observe viral load changes in plasma and oral samples. The study may help tailor future treatment intensity and improve monitoring approaches, with participation lasting through treatment and follow-up up to three months post-radiotherapy.
CONDITIONS
HPV-associated Oropharyngeal Carcinoma (HPV-OPC)
M
Martina Lojová, PhD
M
Martin Bartošík, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Masaryk Memorial Cancer Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Approximately 7 months including follow-up
Participants provide oral swabs, oral cavity washings, and blood samples before treatment, at week 4 of radiotherapy, at the end of radiotherapy (around week 7), and three months after treatment to monitor HPV viral load.
4 visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nasim Izadi, Johana Strmiskova, Milan Anton...
https://pubmed.ncbi.nlm.nih.gov/39420658/Dipon Das, Shun Hirayama, Ling Aye...
https://pubmed.ncbi.nlm.nih.gov/40925715/Eleni M Rettig, Daniel L Faden, Shaiba Sandhu...
https://pubmed.ncbi.nlm.nih.gov/35262203/Nasim Izadi, Ravery Sebuyoya, Ludmila Moranova...
https://pubmed.ncbi.nlm.nih.gov/34753575/Masaryk Memorial Cancer Institute
Lead Sponsor